Compare IDEXX Laboratories, Inc. (IDXX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vistra Corp — how do they compare? IDEXX Laboratories, Inc. trades at $558.29 (market cap $44.48B), while Vistra Corp trades at $161.44 (market cap $53.27B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.58% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | VST | |
|---|---|---|
Market Cap | $44.48B | $53.27B |
Sector | Health | Technology |
52-Week High | $766.68 | $217.92 |
52-Week Low | $520.87 | $134.71 |
Enterprise Value | $45.38B | $75.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Vistra Corp (VST) trades at $157.99, up 1.64% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings beat ($2.87 vs $1.32 expected) after previous misses, with 2026 revenue projected at $19.4B and net profit margin improving to 11.52%. Recent news highlights Vistra's positioning as a potential beneficiary of AI-driven power demand growth.
Wall Street maintains strong bullish sentiment with 91% buy ratings and a $253 consensus price target representing 60% upside potential. Key risks include power price volatility, high debt levels, and project execution challenges. The company's long-term power purchase agreements with major tech firms provide revenue visibility, but investors should monitor Q2 2026 earnings due August 7th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
